Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor

Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor

Bruton tyrosine kinase (BTK) inhibitors have become an important therapy for untreated and previously treated patients with chronic lymphocytic leukemia (CLL). Despite improved outcomes, rare adverse events, such as invasive fungal infections, have been reported with the use of first-generation BTK...

Full description

Bibliographic Details
Main Authors: Omar Alkharabsheh, Alhareth Alsayed, Diana M. Morlote, Amitkumar Mehta
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Current Oncology
Subjects:
CLL
acalabrutinib
invasive aspergillosis
Online Access:https://www.mdpi.com/1718-7729/28/1/81
id doaj-2a71315a91a1467a81a5730f4a9ff76b
record_format Article
spelling doaj-2a71315a91a1467a81a5730f4a9ff76b2021-09-20T10:12:06ZengMDPI AGCurrent Oncology1198-00521718-77292021-02-01288183784110.3390/curroncol28010081Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase InhibitorOmar Alkharabsheh0Alhareth Alsayed1Diana M. Morlote2Amitkumar Mehta3Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USAMitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USADepartment of Pathology, University of Alabama at Birmingham, Birmingham, AL 35233, USAO’Neal Comprehensive Cancer Center at UAB, University of Alabama at Birmingham, Birmingham, AL 35233, USABruton tyrosine kinase (BTK) inhibitors have become an important therapy for untreated and previously treated patients with chronic lymphocytic leukemia (CLL). Despite improved outcomes, rare adverse events, such as invasive fungal infections, have been reported with the use of first-generation BTK inhibitors. Invasive fungal infections carry a high morbidity and mortality risk. There have been several case reports describing the association between aspergillosis and ibrutinib treatment, but none with acalabrutinib, to our knowledge. In this case report, we describe a patient with CLL who developed an intracranial <i>Aspergillus fumigatus</i> infection while receiving acalabrutinib.https://www.mdpi.com/1718-7729/28/1/81CLLacalabrutinibinvasive aspergillosis
collection DOAJ
language English
format Article
sources DOAJ
author Omar Alkharabsheh
Alhareth Alsayed
Diana M. Morlote
Amitkumar Mehta
spellingShingle Omar Alkharabsheh
Alhareth Alsayed
Diana M. Morlote
Amitkumar Mehta
Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor
Current Oncology
CLL
acalabrutinib
invasive aspergillosis
author_facet Omar Alkharabsheh
Alhareth Alsayed
Diana M. Morlote
Amitkumar Mehta
author_sort Omar Alkharabsheh
title Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor
title_short Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor
title_full Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor
title_fullStr Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor
title_full_unstemmed Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor
title_sort cerebral invasive aspergillosis in a case of chronic lymphocytic leukemia with bruton tyrosine kinase inhibitor
publisher MDPI AG
series Current Oncology
issn 1198-0052
1718-7729
publishDate 2021-02-01
description Bruton tyrosine kinase (BTK) inhibitors have become an important therapy for untreated and previously treated patients with chronic lymphocytic leukemia (CLL). Despite improved outcomes, rare adverse events, such as invasive fungal infections, have been reported with the use of first-generation BTK inhibitors. Invasive fungal infections carry a high morbidity and mortality risk. There have been several case reports describing the association between aspergillosis and ibrutinib treatment, but none with acalabrutinib, to our knowledge. In this case report, we describe a patient with CLL who developed an intracranial <i>Aspergillus fumigatus</i> infection while receiving acalabrutinib.
topic CLL
acalabrutinib
invasive aspergillosis
url https://www.mdpi.com/1718-7729/28/1/81
work_keys_str_mv AT omaralkharabsheh cerebralinvasiveaspergillosisinacaseofchroniclymphocyticleukemiawithbrutontyrosinekinaseinhibitor
AT alharethalsayed cerebralinvasiveaspergillosisinacaseofchroniclymphocyticleukemiawithbrutontyrosinekinaseinhibitor
AT dianammorlote cerebralinvasiveaspergillosisinacaseofchroniclymphocyticleukemiawithbrutontyrosinekinaseinhibitor
AT amitkumarmehta cerebralinvasiveaspergillosisinacaseofchroniclymphocyticleukemiawithbrutontyrosinekinaseinhibitor
_version_ 1717374488059838464

Similar Items